本帖最后由 老马 于 2012-1-13 21:20 编辑 , ^$ Z( z/ \3 z/ s+ J- r# w S
8 I6 x" J! o8 g" \2 f爱必妥和阿瓦斯丁的比较6 w7 J& E3 z4 a
5 W" L- {$ f. `$ d1 C- E
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ S- d! Y6 S' z1 e/ D( e" x
8 e4 K* U" g8 m2 l: @
% X/ G8 D* k: c! nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, [/ q, [' {+ S! V
==================================================# i. p% D( r" \+ Y, K2 ]$ I( l0 _: r+ `
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 i' f u( L( c( J, i3 dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 q% B! z2 s1 @& ^+ r; D+ ]Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.5 v6 R+ O% a1 E5 @6 s: M0 T: [
|
显身卡
